Ran Frenkel, Chief Development Operations Officer at Karyopharm Therapeutics Inc. (KPTI), sold 9,916 shares at $11.25 ($112K) on 2017-11-07, disclosed to the SEC on 2017-11-09.
Open-market sale of $112k KPTI by Chief Development Operations Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.25 | 4,958 | $56K | 50.0% |
| 2 | $11.25 | 4,958 | $56K | 50.0% |
| Total | $11.25 avg | 9,916 | $112K | 100% |
| Filing → |
| KPTI | SELL | 2022-02-09 | $20K | — | Filing → |
| KPTI | SELL | 2021-02-22 | $43K | — | Filing → |
| KPTI | SELL | 2021-02-17 | $32K | — | Filing → |